IRIDEX Announces the Appointment of Doris Engibous to its Board of Directors
April 21 2020 - 8:00AM
IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative
ophthalmic laser-based medical products for the treatment of
glaucoma and retinal diseases, today announced the appointment of
Doris Engibous to its board of directors effective April 20, 2020.
The Company will also nominate Ms. Engibous for re-election to the
board at its 2020 Annual Meeting of Stockholders.
“I am delighted to welcome Doris to our board of directors,”
said Robert Gunst, chairman of the board of IRIDEX. “Doris has an
ideal background given her extensive experience leading and guiding
successful medical technology companies. Her skills are very
complementary to our team and we are confident she can help guide
the Company to greater business success and increased shareholder
value.”
On her appointment, Ms. Engibous commented, “I am honored to
join the IRIDEX board as they advance commercialization and expand
their market share with a unique laser-based approach to glaucoma
treatment. I look forward to contributing my expertise to the
Company’s commercialization strategy to further IRIDEX's position
in treating sight-threatening diseases.”
Maria Sainz has notified the IRIDEX board that she will not
stand for re-election at the Company’s 2020 Annual Shareholder
Meeting. Ms. Sainz has served on the IRIDEX board since April 2018.
The entire IRIDEX team greatly appreciates her service and
insights, which have contributed significant value to shareholders
and the growth of the business.
Following the retirement of Ms. Sainz, the Company’s board will
be composed of six directors.
About Doris EngibousMs. Engibous has been an
independent consultant and advisor to medical technology companies
and executives since 2010. She currently serves on the board of
directors of Imricor Medical Systems Inc., a pioneer and leader in
developing MRI-compatible products for cardiac catheter ablation
procedures and GI Supply Inc., a family-owned provider of
innovative medical products. Previously, Ms. Engibous served on the
board of directors of Natus Medical Inc., a $500 million leading
provider of healthcare products, as well as the National Kidney
Foundation serving Minnesota, the Dakotas and Iowa.
From 2004 to 2010, Ms. Engibous served as President and CEO of
Hemosphere Inc., an early stage, venture capital funded medical
technology company, prior to its acquisition by CryoLife Inc. Prior
to 2004, Ms. Engibous served 18 years in several executive
capacities at Nellcor and its successors Nellcor Puritan Bennett
Inc., Mallinckrodt Inc., and Tyco Healthcare including President of
Nellcor, and was responsible for the integration of Nellcor into
Mallinckrodt and later Tyco Healthcare. She holds a Bachelor of
Science degree in Chemical Engineering from the University of
Michigan.
About IRIDEXIRIDEX is a
worldwide leader in developing innovative and versatile laser-based
medical systems, delivery devices and consumable instrumentation
for the ophthalmology market. The Company’s proprietary MicroPulse®
technology delivers a differentiated treatment that provides safe,
effective, and proven treatment for targeted sight-threatening eye
conditions. IRIDEX’s current product line is used for the
treatment of glaucoma, diabetic macular edema (DME) and other
retinal diseases. IRIDEX products are sold in the United
States and Germany through a direct sales force and in more than
100 countries through a network of independent distributors. For
further information, visit the IRIDEX website at
http://www.iridex.com/.
Investor Relations Contact Leigh Salvo (415)
937-5404 investors@iridex.com
Media Contact Jamie Hall Pascale
Communications, LLC. (724) 417-0167 pr@iridex.com
IRIDEX (NASDAQ:IRIX)
Historical Stock Chart
From Aug 2024 to Sep 2024
IRIDEX (NASDAQ:IRIX)
Historical Stock Chart
From Sep 2023 to Sep 2024